# A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

> **NCT01050998** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 516 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Mavrilimumab 10 mg
- **BIOLOGICAL:** Mavrilimumab 30 mg
- **BIOLOGICAL:** Mavrilimumab 50 mg
- **BIOLOGICAL:** Mavrilimumab 100 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01050998
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-05
- **Primary completion:** 2011-06-09
- **Final completion:** 2012-07-27
- **Target enrollment:** 516 (ACTUAL)
- **Last updated:** 2018-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01050998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01050998, "A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01050998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*